Clinical data
AHFS/ Monograph
Routes of
Tablets, injection
ATC code N01AH05 (WHO)
Legal status
Legal status
Pharmacokinetic data
Protein binding > 95%
Metabolism Hepatic
CAS Number 144-14-9 YesY
PubChem (CID) 8944
DrugBank DB00913 YesY
ChemSpider 8600 YesY
UNII 71Q1A3O279 YesY
KEGG D02941 YesY
ChEBI CHEBI:61203 YesY
Chemical and physical data
Formula C22H28N2O2
Molar mass 352.47 g/mol
3D model (Jmol) Interactive image
Melting point 83 °C (181 °F)
 NYesY (what is this?)  (verify)

Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s.[1] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.

Anileridine is no longer manufactured in the US or Canada.[2] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate [3] It is also under international control per UN treaties.


As tablets or injection.[4]


Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[5] It is mostly metabolized by the liver.


This article is issued from Wikipedia - version of the 6/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.